Taipei, 16 May 2022 – REGiMMUNE Limited, a biopharmaceutical company focused on creating innovative immunotherapies for rare diseases and cancer, today announced Charlie Hsu, a seasoned financial executive, join the company’s management team as Chief Financial Officer (CFO).

Charlie brings more than 25 years of business experience in finance management and equity investment in both tech and biotech sectors. Before joining REGiMMUNE, he served as spokesman in various Taiwan listed companies, and SVP in globally reputable venture capital and private equity firm. In 2017, Charlie led ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company, successfully listed in Taipei Exchange.

“Charlie’s deep and extensive experience in leading the financial operations is a great asset in supporting REGiMMUNE’s growth trajectory, licensing, M&A and integration roadmaps, as well as operational efficiency.” stated Mr. Kenzo Kosuda, President and CEO of REGiMMUNE. “We welcome him to our team and look forward to his contributions in growing the long-term value of our company.”

“I am thrilled to join REGiMMUNE at this exciting time. The high potential for growth and value creation at REGiMMUNE is tremendous, given the smart and passionate people, strong technology, and worldwide footprint ,” said Charlie Hsu. “REGiMMUNE is particularly compelling given its advanced clinical program and antibody drug candidates, all of which are in indications with significant unmet medical needs. I look forward to taking this next step in my career to help realize the company’s potential to bring novel autoimmune and immuno-oncology therapeutics to clinicians and patients.”

Charlie Hsu holds master and bachelor degree in business administration from the National Chengchi University.